METHYLHYDROXYNANDROLONE (MOHN, MHN), also known as 4-HYDROXY-17Α-METHYL-19-NORTESTOSTERONE, as well as 4,17Β-DIHYDROXY-17Α-METHYLESTR-4-EN-3-ONE, is a synthetic, orally active anabolic–androgenic steroid (AAS) and a 17α-alkylated derivative of nandrolone (19-nortestosterone) which was never marketed.[1] It was first described in 1964, but was not developed for clinical use.[2] The drug re-emerged in 2004 when it started being sold on the Internet as a "dietary supplement".[3] MOHN joined other AAS as a controlled substance in the United States on 20 January 2005.[4]
